Free/total prostate specific antigen ratio for prostate cancer detection: A prospective blind study

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2439-2443

  Yang, Chi Rei ^a,b,c   Su, Chung Knang ^a,b   Chiu, Kun Yuan ^a,c   Ho, Hao Chung ^a   Ou, Yen Chuan ^a,b,c,d   Cheng, Cheng Li ^a   Lee, Huei ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHI NAN UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Free prostate specific antigen; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD;

EID: 22944442247     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. Catalona WJ, Richie JP, Ahmann FR, Hudson, MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR and Dalkin BL: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of PC: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
3. Catalona WJ, Hudson MA and Scardino PT: Selection of optimal prostate specific antigen cutoffs for early detection of PC: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
4. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson P and Lilja H: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of PC. J Urol 150: 100-105, 1993.
5. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL and Stamey TA: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
6. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of PC screening. JAMA 274: 1214-1220, 1995.
7. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J and Brawer MK: Measurement of the proportion of free to total prostate-specific antigen improves the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
8. Martinez-Pineiro L, Tabernero A and Contreras T: Determination of the percentage of the free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml. Eur Urol 37: 289-296, 2000.
9. Woodrum DL, Brawer MK, Partin AW, Catalona WJ and Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of PC. J Urol 159: 5-12, 1998.
10. Lein M, Stephan C, Jung K, Schnorr D and Loening S: Relation of free PSA/total PSA in serum for differentiating between patients with PC and benign hyperplasia of the prostate: which cutoff should be used? Cancer Invest 16 (1): 45-49, 1998.
11. Cancer Registry Annual Report: Department of Health. The Executive Yuan, R.O.C. August 1995.
12. General Health Statistics 1996: In: Health and Vital Statistics. Department of Health. The Executive Yuan, R.O.C. September 2002.
13. Partin AW and Carter HB: The use of prostate-specific antigen and free/total prostate specific antigen in the diagnosis of localized PC. Urol Clin N Amer 23: 531-540, 1996.
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG and Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of PC from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998.
15. Graves HB: Standardization of immunoassays for prostate-specific antigen. A problem of prostate-specific antigen complexation or a problem of assay design? Cancer 72: 3141, 1993.
16. Elgamal AA, Cornillie FJ and Van Poppel HP: Free-to-total prostate specific antigen ratio as a single test for detection of significant Tie PC. J Urol 156: 1042-1047, 1996.
17. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, Schurenkamper P and Loening SA: Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42: 1026-1033, 1996.
18. Yang CR, Ou YC, Horng YY and Lee HS: The variation of percent free prostate-specific antigen determined by two different assays. Anticancer Res 23: 707-711, 2003.
19. Bangma CH, Kranse R, Blijengerg BG and Schroder FH: The value of screening tests in the detection of PC. Results of a retrospective evaluation of 1726 men. Urology 46: 773-778, 1995.
20. Chan DW, Sokoll LJ and Jones KA: Clinical evaluation of two free PSA assays in combination with different total PSA assay. J Urol 157(suppl): 112, 1997.
21. AHEL MZ, Kovacic K and Tarle M: Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis. Anticancer Res 21: 1363-1366, 2001.
22. Oremek GM, Sapoutzis N, Eden F and Jonas D: Complexed PSA in routine diagnosis. Anticancer Res 23: 975-978, 2003.